Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single arm, single-dose, safety and pharmacokinetic study of ReliBeta (Interferon beta-1a 2x30 micrograms pre-filled syringe) from Reliance Life Sciences Pvt. Ltd., India in normal, healthy, adult, human subjects under fasting conditions

Trial Profile

A single arm, single-dose, safety and pharmacokinetic study of ReliBeta (Interferon beta-1a 2x30 micrograms pre-filled syringe) from Reliance Life Sciences Pvt. Ltd., India in normal, healthy, adult, human subjects under fasting conditions

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2019

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Pharmacokinetics
  • Sponsors Reliance Life Sciences
  • Most Recent Events

    • 25 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top